Overview
PARIS (July 24, 2015) – McDermott Will & Emery advised DBV Technologies on its public offering of new shares in the form of American Depositary Shares (ADS) in the US amounting to US$281.5 million (approximately €255 million).
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin® The company is advancing this unique technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such an anaphylactic shock.
DBV Technologies has designed two candidate products: Viaskin® Peanut and Viaskin® Milk. The US Food and Drug Administration referred to Viaskin® Peanut for a pediatric use as an “accelerated program” and a “revolutionary treatment.”
The McDermott corporate and securities team included Emmanuelle Trombe, Bertrand Delafaye, Noëmie Fort and Pierre Menegaux.
The initial announced offering of 3,600,000 ordinary shares in the form of 7,200,000 ADS was raised to 4,140,000 new ordinary shares in the form of 8,280,000 ADS amounting to US$281.5 million. The company trades on The NASDAQ Global Market under the symbol “DBVT” and on Euronext under the symbol “DVB.”
“This transaction represents yet another example of McDermott’s cross-border life science and public markets expertise”, commented Byron Kalogerou, Chair of the Firm’s Life Science Industry Group.
About McDermott
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,100 lawyers, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.
